Latest CAXTON CORP Stock Portfolio
CAXTON CORP Performance:
2025 Q4: 13.55%YTD: 70.38%2024: 51.49%
Performance for 2025 Q4 is 13.55%, and YTD is 70.38%, and 2024 is 51.49%.
About CAXTON CORP and 13F Hedge Fund Stock Holdings
On 2026-02-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, CAXTON CORP reported an equity portfolio of $4.3 Millions as of 31 Dec, 2025.
The top stock holdings of CAXTON CORP are GLD, , AGLE. The fund has invested 64.5% of it's portfolio in SPDR GOLD TR and 8.3% of portfolio in BERKSHIRE HATHAWAY INC DEL.
The fund managers got completely rid off REZOLUTE INC (RZLT) and ENLIVEN THERAPEUTICS INC stocks. They significantly reduced their stock positions in COMPASS THERAPEUTICS INC (CMPX), MIND MEDICINE MINDMED INC (MNMD) and LEXEO THERAPEUTICS INC. CAXTON CORP opened new stock positions in SPYRE THERAPEUTICS INC (AGLE) and X4 PHARMACEUTICALS INC (XFOR). The fund showed a lot of confidence in some stocks as they added substantially to INHIBIKASE THERAPEUTICS INC (IKT) and BERKSHIRE HATHAWAY INC DEL.
The top stock holdings of CAXTON CORP are GLD, , AGLE. The fund has invested 64.5% of it's portfolio in SPDR GOLD TR and 8.3% of portfolio in BERKSHIRE HATHAWAY INC DEL.
The fund managers got completely rid off REZOLUTE INC (RZLT) and ENLIVEN THERAPEUTICS INC stocks. They significantly reduced their stock positions in COMPASS THERAPEUTICS INC (CMPX), MIND MEDICINE MINDMED INC (MNMD) and LEXEO THERAPEUTICS INC. CAXTON CORP opened new stock positions in SPYRE THERAPEUTICS INC (AGLE) and X4 PHARMACEUTICALS INC (XFOR). The fund showed a lot of confidence in some stocks as they added substantially to INHIBIKASE THERAPEUTICS INC (IKT) and BERKSHIRE HATHAWAY INC DEL.
CAXTON CORP Annual Return Estimates Vs S&P 500
Our best estimate is that CAXTON CORP made a return of 13.55% in the last quarter. In trailing 12 months, it's portfolio return was 70.38%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| spyre therapeutics inc | 292,194 |
| x4 pharmaceuticals inc | 62,227 |
New stocks bought by CAXTON CORP
Additions
| Ticker | % Inc. |
|---|---|
| inhibikase therapeutics inc | 73.57 |
| berkshire hathaway inc del | 9.06 |
Additions to existing portfolio by CAXTON CORP
Reductions
| Ticker | % Reduced |
|---|---|
| compass therapeutics inc | -44.87 |
| mind medicine mindmed inc | -41.92 |
| lexeo therapeutics inc | -19.55 |
| kyverna therapeutics inc | -18.31 |
| spdr gold tr | -4.42 |
| sab biotherapeutics inc | -3.73 |
CAXTON CORP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| rezolute inc | -18,676,100 |
| enliven therapeutics inc | -268,106 |
| bicara therapeutics inc | -172,760 |
CAXTON CORP got rid off the above stocks
Sector Distribution
CAXTON CORP has about 80.2% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 80.2 |
| Healthcare | 19.8 |
Market Cap. Distribution
CAXTON CORP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 80.2 |
| SMALL-CAP | 8.6 |
| MID-CAP | 6.8 |
| MICRO-CAP | 4.4 |
Stocks belong to which Index?
About 5.2% of the stocks held by CAXTON CORP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 94.8 |
| RUSSELL 2000 | 5.2 |
CAXTON CORP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of CAXTON CORP
CAXTON CORP has 11 stocks in it's portfolio. proved to be the most loss making stock for the portfolio. GLD was the most profitable stock for CAXTON CORP last quarter.
Last Reported on: 13 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 6.83 | 8,919 | 292,194 | new | |||
| CMPX | compass therapeutics inc | 3.70 | 29,495 | 158,386 | reduced | -44.87 | ||
| CNTX | context therapeutics inc | 0.63 | 18,403 | 27,053 | unchanged | 0.00 | ||
| GLD | spdr gold tr | 64.50 | 6,964 | 2,759,900 | reduced | -4.42 | ||
| IKT | inhibikase therapeutics inc | 1.36 | 28,453 | 58,328 | added | 73.57 | ||
| MNMD | mind medicine mindmed inc | 4.91 | 15,688 | 210,058 | reduced | -41.92 | ||
| RZLT | rezolute inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| SABS | sab biotherapeutics inc | 0.92 | 10,527 | 39,371 | reduced | -3.73 | ||
| XFOR | x4 pharmaceuticals inc | 1.45 | 15,557 | 62,227 | new | |||
| berkshire hathaway inc del | 8.34 | 710 | 356,771 | added | 9.06 | |||
| kyverna therapeutics inc | 4.12 | 18,773 | 176,468 | reduced | -18.31 | |||
| lexeo therapeutics inc | 3.23 | 13,943 | 138,453 | reduced | -19.55 | |||
| enliven therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | |||
| bicara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | |||